Cardiovasculaire Geneeskunde.nl

Prevalence and burden of risk associated with Atrial Fibrillation

Slides (presentatie) - Nov. 8, 2011

Prevalence & burden of risk associated with Atrial Fibrillation


Dr. Martin Lowe– Consultant cardiologist
University College London, United Kingdom

 


Bekijk of download de presentatie

klik voor bekijken op onderstaande afbeeldingen





Cardiovascular Exchange Summit 2011

Atrial Fibrillation Demographics by Age

AF – an epidemic

AF Increases Mortality

Hospitalisation Rates Among AF Patients

AF treatment - Stroke Prevention & Symptom Management

Control of Ventricular Rate in Atrial Fibrillation

Impact of Drug Therapy on Exercise Ventricular Rate in Atrial Fibrillation

Vaughan Williams Classification of Antiarrhythmic Drugs

Rhythm control for AF-Duration and Cardioversion

Atrial Fibrillation-Antiarrhythmic Therapy

AADs for AF

Dronedarone

ESC Guidelines for Paroxysmal AF Management

Dronedarone - NICE Guidance

Rate vs Rhythm control-AFFIRM - all-cause mortality

AFFIRM - Prevalence of SR at follow-up

Non-pharmacological AF Treatment Options

Outcome After AVN Ablation and Pacing

The Pulmonary Vein Potential

Location of Triggering Foci

Initiating and Maintaining Atrial Fibrillation

Progression of paroxysmal to persistent AF-HATCH Score

AF ablation - randomised trials

AF ablation – heart failure pts

AF – Stroke prevention

CHA2DS2VASc Score

Efficacy of Warfarin Compared with Control for the Prevention of Ischaemic Stroke

Beyond warfarin…

Dabigatran – RE-LY trial

Stroke prevention - Dabigatran

Anticoagulation in AF

AF – an evolving epidemic

Deze inhoud is bedoeld voor medische professionals. Om dit te bekijken is registratie noodzakelijk. Registreer gratis voor onbeperkte toegang tot ons educatief materiaal.

Deel deze pagina met collega's en vrienden: